Research programme: coronavirus inhibitors - EpiCept Corporation

Drug Profile

Research programme: coronavirus inhibitors - EpiCept Corporation

Alternative Names: MX-128533

Latest Information Update: 07 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; National Institute of Allergy and Infectious Diseases
  • Class Ketones; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Severe acute respiratory syndrome

Most Recent Events

  • 09 Jan 2006 Maxim Pharmaceuticals has been acquired and merged into EpiCept Corporation
  • 01 Mar 2004 Coronavirus inhibitors are available for licensing worldwide (http://www.maxim.com)
  • 30 Jan 2004 Preclinical trials in Severe acute respiratory syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top